Rat Study Reveals the Womb May Shield Babies With Classic Galactosemia Before Birth

Classic galactosemia is one of those rare genetic diseases that has long puzzled physicians. Babies born without a working copy of the enzyme galactose-1-phosphate uridylyltransferase, known simply as GALT, cannot properly break down galactose, a sugar found in milk and many other foods. Left untreated with a galactose-restricted diet, the condition can be lethal in the newborn period. Yet even when infants are diagnosed early and placed on strict dietary management, many go on to experience lifelong complications ranging from speech and motor difficulties to cognitive challenges and, in girls, premature ovarian insufficiency. A new study in a rat model of the disease now points to a provocative possibility: some of the damage attributed to classic galactosemia may begin before birth, and the metabolic environment inside the womb may determine just how much harm accumulates during those critical months of development.

The research, conducted by Shauna A. Rasmussen, Catherine M. Lemons, and colleagues in the laboratory of Judith L. Fridovich-Keil and published in PLOS Genetics, set out to test a question that has lingered in the galactosemia field for years. Previous reports had documented that galactose metabolites are already elevated in utero in human fetuses with classic galactosemia, raising the concern that long-term complications might trace their origins to the prenatal period. But the picture was complicated by other studies showing that elevated galactose metabolites measured after birth do not reliably predict which children will later develop developmental problems. That disconnect left researchers without a clear way to connect the biochemical abnormalities of the disease to the clinical outcomes that matter most to families.

To untangle this relationship, the team turned to a GALT-null rat model, animals engineered to completely lack functional GALT enzyme, mirroring the profound enzyme deficiency seen in the most severe human cases. The experimental design was elegantly simple in concept but powerful in its implications. The researchers arranged rat crosses so that GALT-null pups developed inside mothers with different levels of GALT activity, and alongside littermates who also differed in their genetic makeup. Some GALT-null fetuses grew within a GALT-null dam, others within a heterozygous dam carrying one working copy of the gene, and some developed alongside heterozygous siblings while others did not. The logic was that GALT activity present outside the fetus itself, but still within the shared maternal-fetal compartment, might help clear galactose metabolites from the environment surrounding the developing animal.

That reasoning proved correct. Across all of the crosses, GALT-null fetal pups showed elevated galactose metabolites compared with controls, confirming that the fetal deficiency alone is enough to drive biochemical abnormalities before birth. But the magnitude of those elevations varied dramatically depending on the genetic background of the mother and the siblings sharing the pregnancy. When the dam was heterozygous and some of the siblings were heterozygous as well, the level of galactitol, a sugar alcohol that accumulates when galactose cannot be fully metabolized, in the amniotic fluid of GALT-null fetal pups at gestational day 21 was comparable to levels previously reported from second-trimester human amniotic fluid in classic galactosemia pregnancies. In other words, a partially protected womb environment produced a biochemical profile that closely resembled the real human situation.

The contrasts at the other end of the spectrum were striking. When the dam herself was GALT-null but some siblings were heterozygous, the median galactitol level in the amniotic fluid was 2.45-fold higher than in the partially protected setting. And when both the dam and all of the siblings were GALT-null, leaving no source of GALT activity anywhere in the maternal-fetal compartment outside the fetus, the median amniotic fluid galactitol level soared to 5.67-fold higher. These numbers demonstrate that the metabolic burden carried by a GALT-deficient fetus is not fixed by the fetus’s own genotype alone. It is shaped, and can be substantially amplified or buffered, by the enzyme activity of the surrounding pregnancy, from the mother’s own metabolism to that of her other unborn offspring.

Perhaps the most consequential finding of the study concerned fetal growth. GALT-null fetal pups showed significant growth delay in utero, but only under one specific condition: when the dam and all of the siblings were GALT-null. In every other cross, the GALT-null fetuses grew normally despite carrying moderately elevated galactose metabolites. This dissociation between metabolite levels and outcome is critical. It suggests that the sheer presence of excess galactose metabolites in utero is not, by itself, sufficient to impair fetal development. Instead, harm appears to require a threshold, one that is only crossed when the entire maternal-fetal environment lacks GALT activity and metabolites accumulate to their highest levels.

The implications for human classic galactosemia follow directly from this pattern. Because classic galactosemia is an autosomal recessive condition, most babies born with the disease have parents who are carriers, meaning the mother is typically heterozygous with one functional copy of the GALT gene. If the rat findings translate to humans, a carrier mother may provide at least partial protection in utero, her own GALT activity helping to limit the accumulation of galactose metabolites in the shared fetal environment. The study’s authors note that the full rescue of fetal growth by gestation within a heterozygous dam, despite the persistence of moderately elevated metabolites, raises exactly this possibility: that babies with classic galactosemia developing within a carrier mother might be at least partially shielded from the adverse prenatal consequences of their enzyme deficiency.

The work also helps resolve a longstanding tension in the galactosemia literature. If postnatal metabolite levels do not predict long-term complications, as prior studies have documented, then the search for the origins of those complications may need to look earlier in development, and to look not just at the levels of metabolites but at the context in which they accumulate. The rat model now offers a way to do precisely that, by independently manipulating the genotype of the dam, the fetus, and the siblings to disentangle their respective contributions. This kind of experimental control is impossible in human pregnancies, which is why the animal model represents such a significant methodological advance for the field.

There remain important caveats and open questions. Rats are not humans, and the developmental timeline of a rodent pregnancy differs substantially from that of a human gestation. The study measured outcomes at gestational day 21, near the end of the rat pregnancy, and focused on growth and metabolite accumulation rather than on the long-term neurological and ovarian outcomes that define the human disease. Whether the protective effect of a heterozygous dam extends to the brain and reproductive system, and whether it persists after birth once the infant is exposed to dietary galactose, will require further work. Still, the study establishes a clear principle: the prenatal metabolic environment is a modifiable variable in classic galactosemia, and understanding it may reshape how scientists think about when and how the disease’s complications begin.

For families affected by classic galactosemia, the research offers a measure of reassurance grounded in data rather than hope alone. The vast majority of children with the condition are carried by carrier mothers, the very scenario in which the rat model showed full rescue of fetal growth. While the findings do not diminish the importance of newborn screening and prompt dietary intervention after birth, they suggest that the window of greatest vulnerability may be narrower, or at least more conditional, than previously feared. They also open a concrete research agenda: identifying which aspects of the maternal-fetal environment confer protection, and whether interventions that mimic that protection could one day benefit the subset of pregnancies where no GALT activity is available anywhere in the compartment. In a disease where decades of strict dieting have failed to prevent all complications, the idea that prevention might begin in the womb is a compelling new direction.

Subject of Research: Prenatal metabolic consequences of GALT deficiency in a rat model of classic galactosemia

Article Title: Prenatal consequences of GALT deficiency in a rat model of classic galactosemia

Article References: Rasmussen, S. A., Lemons, C. M., Seemiller, M. M., Dallas, S. R., Ledesma, M. C., Wu, Y., Anshen, L. E., Farnham, A., Garrett, O. S., & Fridovich-Keil, J. L. (2026). Prenatal consequences of GALT deficiency in a rat model of classic galactosemia. PLOS Genetics, 22(9), e1012276. https://doi.org/10.1371/journal.pgen.1012276

Image Credits: AI Generated

DOI: 10.1371/journal.pgen.1012276

Keywords: classic galactosemia, GALT deficiency, galactitol, amniotic fluid, prenatal development, rat model, fetal growth, carrier mother, galactose metabolites, PLOS Genetics, metabolic disease, inborn errors of metabolism